retatrutide fda approval status october 2025 Availability & Timeline October 27, 2025: U.K. regulators

A 2021 research review looking at several clinical studies on GLP-1s concluded that once-a-day oral semaglutide is as or more effective at helping with weight loss than the injectable versions

In the light of a recent cohort study by Tang and his colleagues, comprising 4,000 individuals for 3 years, it has been found that TMAO can be a new biomarker for cardiac mortality, MI, or cerebrovascular accidents in addition to increasing cardiac-related mortality by 2.5 times [73, 74]

We will try to minimize this risk by recommending a sulfite urine test to be completed prior to initiating treatment

Within the pancreas, GLP-1 binds receptors on alpha-cells to suppress glucagon secretion, and on beta-cells triggering insulin release, which helps reduce blood glucose.

As early as the mid-20th century, studies of commercial diet programs showed that while short-term weight loss was common, regaining weight long term was the norm